Modeling of autism genetic variations in mice: Focusing on synaptic and microcircuit dysfunctions

Developmental Neuroscience

Volumn 34, Issue 2-3, 2012, Pages 88-100

  Qiu, Shenfeng ^a   Aldinger, Kimberly A ^a   Levitt, Pat ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Autism; Chromosomal abnormality; Copy number variation; Genetic mutation; Mouse; Neural development; Synaptic dysfunction

Indexed keywords

4 AMINOBUTYRIC ACID; AMPA RECEPTOR; CONTACTIN; METHYL CPG BINDING PROTEIN 2; N METHYL DEXTRO ASPARTIC ACID; NEUREXIN; NEUROLIGIN; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR FOXP2; UROKINASE;

ANIMAL MODEL; ARTICLE; AUTISM; BRAIN DEVELOPMENT; CELL DENSITY; CELL FUNCTION; CELL STRUCTURE; CHROMOSOME ABERRATION; CLINICAL FEATURE; COMORBIDITY; DENDRITIC SPINE; ENDOPHENOTYPE; EXON; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GENETIC RISK; GENETIC VARIABILITY; HAPLOINSUFFICIENCY; NERVE CELL; NERVE CELL DIFFERENTIATION; NERVE FIBER; NONHUMAN; NONSENSE MUTATION; PATHOPHYSIOLOGY; POSTSYNAPTIC DENSITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TERATOLOGY;

ANIMALS; AUTISTIC DISORDER; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; MICE; NERVE NET; NEURONS; SYNAPSES;

EID: 84866305540     PISSN: 03785866     EISSN: 14219859     Source Type: Journal    
DOI: 10.1159/000336644     Document Type: Article

References (136)

1. Kogan MD, et al: Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics 2009; 124: 1395-1403.
2. Geschwind DH, Levitt P: Autism spectrum disorders: Developmental disconnection syndromes. Curr Opin Neurobiol 2007; 17: 103-111.
3. Abrahams BS, Geschwind DH: Advances in autism genetics: on the threshold of a new neurobiology. Nat Rev Genet 2008; 9: 341- 355.
4. Walsh CA, Morrow EM, Rubenstein JL: Autism and brain development. Cell 2008; 135: 396-400.
5. Scherer SW, Dawson G: Risk factors for autism: Translating genomic discoveries into diagnostics. Hum Genet 2011; 130: 123-148.
6. Levitt P, Campbell DB: The genetic and neurobiologic compass points toward common signaling dysfunctions in autism spectrum disorders. J Clin Invest 2009; 119: 747-754.
7. Moy SS, Nadler JJ: Advances in behavioral genetics: Mouse models of autism. Mol Psychiatry 2008; 13: 4-26.
8. Schaaf CP, Zoghbi HY: Solving the autism puzzle a few pieces at a time. Neuron 2011; 70: 806-808.
9. Huttenlocher PR, Dabholkar AS: Regional differences in synaptogenesis in human cerebral cortex. J Comp Neurol 1997; 387: 167- 178.
10. Casanova MF, et al: A topographic study ofminicolumnar core width by lamina comparison between autistic subjects and controls: Possible minicolumnar disruption dueto an anatomical element in-common to multiple laminae. Brain Pathol 2010; 20: 451-458.
11. Hutsler JJ, Zhang H: Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. Brain Res 2010; 1309: 83-94.
12. Irwin SA, et al: Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: A quantitative examination. Am J Med Genet2001; 98: 161-167.
13. Pfeiffer BE, Huber KM: Fragile X mental retardation protein induces synapse lossthrough acute postsynaptic translational regulation. J Neurosci 2007; 27: 3120-3130.
14. Zoghbi HY: Postnatal neurodevelopmental disorders: Meeting at the synapse? Science 2003; 302: 826-830.
15. State MW: The genetics of child psychiatricdisorders: focus on autism and Tourette syndrome. Neuron 2010; 68: 254-269.
16. Thompson BL, Levitt P: The clinical-basic interface in defining pathogenesis in disordersof neurodevelopmental origin. Neuron 2010; 67: 702-712.
17. Persico AM, Bourgeron T: Searching for ways out of the autism maze: Genetic, epigenetic and environmental clues. Trends Neurosci 2006; 29: 349-358.
18. Silverman JL, et al: Behavioural phenotyping assays for mouse models of autism. Nat Rev Neurosci 2010; 11: 490-502.
19. Aldinger KA, et al: SnapShot: Genetics of autism. Neuron 2011; 72: 418-418 e1.
20. Insel TR: The challenge of translation in socialneuroscience: A review of oxytocin, vasopressin,and affiliative behavior. Neuron2010; 65: 768-779.
21. El-Fishawy P, State MW: The genetics of autism:key issues, recent findings, and clinicalimplications. Psychiatr Clin North Am 2010;33: 83-105.
22. State MW, Levitt P: The conundrums of understanding genetic risks for autism spectrumdisorders. Nat Neurosci 2011; 14: 1499-1506.
23. Toro R, et al: Key role for gene dosage andsynaptic homeostasis in autism spectrumdisorders. Trends Genet 2010; 26: 363-372.
24. Coba MP, et al: Neurotransmitters drive combinatorial multistate postsynaptic densitynetworks. Sci Signal 2009; 2:ra19.
25. Betancur C, Sakurai T, Buxbaum JD: Theemerging role of synaptic cell-adhesionpathways in the pathogenesis of autism spectrumdisorders. Trends Neurosci 2009; 32:402-412.
26. Dalva MB, McClelland AC, Kayser MS: Celladhesion molecules: Signalling functions at the synapse. Nat Rev Neurosci 2007; 8: 206-220.
27. Williams ME, de Wit J, Ghosh A: Molecularmechanisms of synaptic specificity in developing neural circuits. Neuron 2010; 68: 9-18.
28. Sudhof TC: Neuroligins and neurexins link synaptic function to cognitive disease. Nature2008; 455: 903-911.
29. Feng J, et al: High frequency of neurexin 1beta signal peptide structural variants inpatients with autism. Neurosci Lett 2006;409: 10-13.
30. Szatmari P, et al: Mapping autism risk loci using genetic linkage and chromosomal rearrangements.Nat Genet 2007; 39: 319-328.
31. Zahir FR, et al: A patient with vertebral, cognitiveand behavioural abnormalities and ade novo deletion of NRXN1alpha. J MedGenet 2008; 45: 239-243.
32. Xu LM, et al: AutismKB: An evidence-based knowledgebase of autism genetics. NucleicAcids Res, E-pub aHead of print.
33. Kattenstroth G, et al: Postsynaptic N-methyl-D -aspartate receptor function requires alpha-neurexins. Proc Natl Acad Sci USA2004; 101: 2607-2612.
34. Lisman J, Raghavachari S: A unified modelof the presynaptic and postsynaptic changesduring LTP at CA1 synapses. Sci STKE 2006;2006:re11.
35. Nicoll RA, Malenka RC: Expression mechanismsunderlying NMDA receptor-dependentlong-term potentiation. Ann NY AcadSci 1999; 868: 515-525.
36. Zhang C, et al: Neurexins physically and functionally interact with GABA(A) receptors.Neuron 2010; 66: 403-416.
37. Etherton MR, et al: Mouse neurexin-1alphadeletion causes correlated electrophysiologicaland behavioral changes consistent withcognitive impairments. Proc Natl Acad Sci USA 2009; 106: 17998-18003.
38. Jamain S, et al: Mutations of the X-linked genes encoding neuroligins NLGN3 andNLGN4 are associated with autism. Nat Genet 2003; 34: 27-29.
39. Laumonnier F, et al: X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. Am J Hum Genet 2004; 74: 552-557.
40. Yan J, et al: Analysis of the neuroligin 3 and 4 genes in autism and other neuropsychiatric patients. Mol Psychiatry 2005; 10: 329-332.
41. Tabuchi K, et al: A neuroligin-3 mutation implicated in autism increases inhibitorysynaptic transmission in mice. Science 2007;318: 71-76.
42. Levitt P, Eagleson KL, Powell EM: Regulation of neocortical interneuron development and the implications for neurodevelopmentaldisorders. Trends Neurosci 2004; 27: 400-406.
43. Rubenstein JL, Merzenich MM: Model of autism: Increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav 2003; 2: 255-267.
44. Jamain S, et al: Reduced social interaction and ultrasonic communication in a mousemodel of monogenic heritable autism. Proc Natl Acad Sci USA 2008; 105: 1710-1715.
45. Hayashi MK, et al: The postsynaptic density proteins Homer and Shank form a polymeric network structure. Cell 2009; 137: 159-171.
46. Bonaglia MC, et al: Identification of a recurrentbreakpoint within the SHANK3 gene in the 22q13.3 deletion syndrome. J Med Genet2006; 43: 822-828.
47. Durand CM, et al: Mutations in the gene encodingthe synaptic scaffolding proteinSHANK3 are associated with autism spectrumdisorders. Nat Genet 2007; 39: 25-27.
48. Roussignol G, et al: Shank expression is sufficient to induce functional dendritic spinesynapses in aspiny neurons. J Neurosci 2005; 25: 3560-3570.
49. Cusmano-Ozog K, Manning MA, HoymeHE: 22q13.3 deletion syndrome: A recognizablemalformation syndrome associated with marked speech and language delay. Am J Med Genet C Semin Med Genet 2007; 145C:393-398.
50. Durand CM, et al: SHANK3 mutations identified in autism lead to modification of dendritic spine morphology via an actin-dependent mechanism. Mol Psychiatry 2012; 17:71-84.
51. Wang X, et al: Synaptic dysfunction and abnormalbehaviors in mice lacking major isoforms of Shank3. Hum Mol Genet 2011; 20:3093-3108.
52. Peca J, et al: Shank3 mutant mice display autistic-like behaviours and striatal dysfunction.Nature 2011; 472: 437-442.
53. Bangash MA, et al: Enhanced polyubiquitination of Shank3 and NMDA receptor in amouse model of autism. Cell 2011; 145: 758-772.
54. Penagarikano O, et al: Absence of CNTNAP2leads to epilepsy, neuronal migrationabnormalities, and core autism-related deficits.Cell 2011; 147: 235-246.
55. Poliak S, et al: Caspr2, a new member of theneurexin superfamily, is localized at the juxtaparanodesof myelinated axons and associateswith K + channels. Neuron 1999; 24: 1037-1047.
56. Sharma S, et al: Genome-wide associationstudies of adolescent idiopathic scoliosis suggest candidate susceptibility genes. Hum Mol Genet 2011; 20: 1456-1466.
57. Strauss KA, et al: Recessive symptomatic focalepilepsy and mutant contactin-associatedprotein-like 2. N Engl J Med 2006; 354:1370-1377.
58. Alarcon M, et al: Linkage, association, andgene-expression analyses identify CNTNAP2as an autism-susceptibility gene. AmJ Hum Genet 2008; 82: 150-159.
59. Arking DE, et al: A common genetic variant in the neurexin superfamily memberCNTNAP2 increases familial risk of autism.Am J Hum Genet 2008; 82: 160-164.
60. Bakkaloglu B, et al: Molecular cytogeneticanalysis and resequencing of contactin associatedprotein-like 2 in autism spectrum disorders.Am J Hum Genet 2008; 82: 165-173.
61. Stein MB, et al: A common genetic variantin the neurexin superfamily memberCNTNAP2 is associated with increased risk for selective mutism and social anxiety-related traits. Biol Psychiatry 2011; 69: 825-831.
62. Vernes SC, et al: A functional genetic link between distinct developmental languagedisorders. N Engl J Med 2008; 359: 2337-2345.
63. Scott-Van Zeeland AA, et al: Altered functionalconnectivity in frontal lobe circuits isassociated with variation in the autism riskgene CNTNAP2. Sci Transl Med 2010; 2: 56-80.
64. Poliak S, et al: Juxtaparanodal clustering ofShaker-like K + channels in myelinated axonsdepends on Caspr2 and TAG-1. J Cell Biol2003; 162: 1149-1160.
65. Schmidt C, et al: Scatter factor/hepatocyte growth factor is essential for liver development.Nature 1995; 373: 699-702.
66. Uehara Y, et al: Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 1995; 373: 702-705.
67. Mukamel Z, et al: Regulation of MET by FOXP2, genes implicated in higher cognitive dysfunction and autism risk. J Neurosci 2011; 31: 11437-11442.
68. Judson MC, Amaral DG, Levitt P: Conserved subcortical and divergent cortical expression of proteins encoded by orthologs of the autism risk gene MET. Cereb Cortex 2011; 21: 1613-1626.
69. Judson MC, et al: Dynamic gene and protein expression patterns of the autism-associated met receptor tyrosine kinase in the developing mouse forebrain. J Comp Neurol 2009; 513: 511-531.
70. Campbell DB, et al: Genetic evidence implicating multiple genes in the MET receptor tyrosine kinase pathway in autism spectrum disorder. Autism Res 2008; 1: 159-168.
71. Campbell DB, et al: A genetic variant that disrupts MET transcription is associated with autism. Proc Natl Acad Sci USA 2006; 103: 16834-16839.
72. Marshall CR, et al: Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet 2008; 82: 477-488.
73. Sousa I, et al: MET and autism susceptibility: family and case-control studies. Eur J Hum Genet 2009; 17: 749-758.
74. Jackson PB, et al: Further evidence that the rs1858830 C variant in the promoter region of the MET gene is associated with autisticdisorder. Autism Res 2009; 2: 232-236.
75. Thanseem I, et al: Further evidence for therole of MET in autism susceptibility. Neurosci Res 2010; 68: 137-141.
76. Campbell DB, et al: Disruption of cerebralcortex MET signaling in autism spectrum disorder. Ann Neurol 2007; 62: 243-250.
77. Voineagu I: Gene expression studies in autism:Moving from the genome to the transcriptomeand beyond. Neurobiol Dis 2012;45: 69-75.
78. Judson MC, Eagleson KL, Levitt P: A newsynaptic player leading to autism risk: Metreceptor tyrosine kinase. J Neurodev Disord2011; 3: 282-292.
79. Powell EM, Mars WM, Levitt P: Hepatocytegrowth factor/scatter factor is a motogen forinterneurons migrating from the ventral to dorsal telencephalon. Neuron 2001; 30: 79-89.
80. Eagleson KL, et al: The autism risk genesMET and PLAUR differentially impact corticaldevelopment. Autism Res 2011; 4: 68-83.
81. Eagleson KL, Bonnin A, Levitt P: Regionandage-specific deficits in gamma-aminobutyricacidergic neuron development in thetelencephalon of the uPAR(-/-) mouse. J Comp Neurol 2005; 489: 449-466.
82. Powell EM, et al: Differential regulation ofthalamic and cortical axonal growth by hepatocytegrowth factor/scatter factor. Dev Neurosci 2003; 25: 197-206.
83. Judson MC, et al: Evidence of cell-nonautonomous changes in dendrite and dendritic spine morphology in the met-signaling-deficient mouse forebrain. J Comp Neurol 2010; 518: 4463-4478.
84. Matsuzaki M, et al: Dendritic spine geometry is critical for AMPA receptor expression in hippocampal CA1 pyramidal neurons.Nat Neurosci 2001; 4: 1086-1092.
85. Qiu S, et al: Circuit-specific intracortical hyperconnectivityin mice with deletion of theautism-associated Met receptor tyrosine kinase.J Neurosci 2011; 31: 5855-5864.
86. Gatchel JR, Zoghbi HY: Diseases of unstable repeat expansion: Mechanisms and common principles. Nat Rev Genet 2005; 6: 743-755.
87. Orr HT, Zoghbi HY: Trinucleotide repeat disorders. Annu Rev Neurosci 2007; 30: 575- 621.
88. Dahlhaus R, El-Husseini A: Altered neuroliginexpression is involved in social deficits in a mouse model of the fragile X syndrome. Behav Brain Res 2010; 208: 96-105.
89. Consortium T: Fmr1 knockout mice: Amodel to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium.Cell 1994; 78: 23-33.
90. Verkerk AJ, et al: Identification of a gene(FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibitinglength variation in fragile X syndrome.Cell 1991; 65: 905-914.
91. Bernardet M, Crusio WE: Fmr1 KO mice asa possible model of autistic features. ScientificWorld Journal 2006; 6: 1164-1176.
92. Peier AM, et al: (Over)correction of FMR1 deficiency with YAC transgenics: Behavioral and physical features. Hum Mol Genet 2000; 9: 1145-1159.
93. Comery TA, et al: Abnormal dendriticspines in fragile X knockout mice: Maturation and pruning deficits. Proc Natl Acad Sci USA 1997; 94: 5401-5404.
94. Bear MF, Huber KM, Warren ST: The mGluR theory of fragile X mental retardation. Trends Neurosci 2004; 27: 370-377.
95. Dolen G, et al: Correction of fragile X syndromein mice. Neuron 2007; 56: 955-962.
96. Hays SA, Huber KM, Gibson JR: Alteredneocortical rhythmic activity states inFmr1 KO mice are due to enhanced mGluR5signaling and involve changes in excitatory circuitry. J Neurosci 2011; 31: 14223-14234.
97. Berry-Kravis E, Knox A, Hervey C: Targeted treatments for fragile X syndrome. JNeurodev Disord 2011; 3: 193-210.
98. Krueger DD, Bear MF: Toward fulfilling the promise of molecular medicine in fragileX syndrome. Annu Rev Med 2011; 62:411-429.
99. Huber KM, et al: Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 2002; 99: 7746-7750.
100. Desai NS, et al: Early postnatal plasticity in neocortex of Fmr1 knockout mice. J Neurophysiol 2006; 96: 1734-1745.
101. Larson J, et al: Age-dependent and selective impairment of long-term potentiation in the anterior piriform cortex of mice lacking the fragile X mental retardation protein. J Neurosci 2005; 25: 9460-9469.
102. Li J, et al: Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. Mol Cell Neurosci 2002; 19: 138-151.
103. Olmos-Serrano JL, et al: Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J Neurosci 2010; 30: 9929- 9938.
104. Bureau I, Shepherd GM, Svoboda K: Circuit and plasticity defects in the developing somatosensory cortex of FMR1 knock-out mice. J Neurosci 2008; 28: 5178-5188.
105. Amir RE, et al: Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet1999; 23: 185-188.
106. Moretti P, Zoghbi HY: MeCP2 dysfunction in Rett syndrome and related disorders. Curr Opin Genet Dev 2006; 16: 276-281.
107. Casanova MF, et al: Rett syndrome as a minicolumnopathy. Clin Neuropathol 2003; 22: 163-168.
108. Belichenko PV, et al: Rett syndrome: 3-D confocal microscopy of cortical pyramidal dendrites and afferents. Neuroreport 1994;5: 1509-1513.
109. Kaufmann WE, Moser HW: Dendritic anomalies in disorders associated with mental retardation. Cereb Cortex 2000; 10: 981-991.
110. Chahrour M, Zoghbi HY: The story of Rett syndrome: from clinic to neurobiology.Neuron 2007; 56: 422-437.
111. Guy J, et al: A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 2001; 27: 322-326.
112. Samaco RC, et al: A partial loss of function allele of methyl-CpG-binding protein 2 predicts a human neurodevelopmental syndrome. Hum Mol Genet 2008; 17: 1718-1727.
113. Zhou Z, et al: Brain-specific phosphorylationof MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 2006; 52: 255-269.
114. Cohen S, et al: Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous system development and function.Neuron 2011; 72: 72-85.
115. Wood L, et al: Synaptic circuit abnormalities of motor-frontal layer 2/3 pyramidal neurons in an RNA interference model of methyl-CpG-binding protein 2 deficiency.J Neurosci 2009; 29: 12440-12448.
116. Chao HT, et al: Dysfunction in GABA signaling mediates autism-like stereotypiesand Rett syndrome phenotypes. Nature2010; 468: 263-269.
117. Ballas N, et al: Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology. Nat Neurosci 2009; 12: 311-317.
118. Estivil X, Armengol L: Copy number variants and common disorders: filling the gapsand exploring complexity in genome-wide association studies. PLoS Genet 2007; 3: 1787-1799.
119. Merikangas AK, Corvin AP, Gallagher L: Copy-number variants in neurodevelopmental disorders: Promises and challenges. Trends Genet 2009; 25: 536-544.
120. Sanders SJ, et al: Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron 2011; 70: 863- 885.
121. Levy D, et al: Rare de novo and transmitted copy-number variation in autistic spectrum disorders. Neuron 2011; 70: 886-897.
122. Sebat J, et al: Strong association of de novo copy number mutations with autism. Science 2007; 316: 445-449.
123. Gilman SR, et al: Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. Neuron 2011; 70: 898-907.
124. Pinto D, et al: Functional impact of global rare copy number variation in autism spectrum disorders. Nature 2010; 466: 368-372.
125. van der Weyden L, Bradley A: Mouse chromosome engineering for modeling human disease. Annu Rev Genomics Hum Genet 2006; 7: 247-276.
126. Glessner JT, et al: Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 2009; 459: 569- 573.
127. Hogart A, et al: The comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13. Neurobiol Dis 2010; 38: 181- 191.
128. Nicholls RD, Knepper JL: Genome organization, function, and imprinting in Prader- Willi and Angelman syndromes. Annu Rev Genomics Hum Genet 2001; 2: 153-175.
129. Nakatani J, et al: Abnormal behavior in a chromosome-engineered mouse model for human 15q11-13 duplication seen in autism. Cell 2009; 137: 1235-1246.
130. Seeburg PH: A-to-I editing: New and old sites, functions and speculations. Neuron 2002; 35: 17-20.
131. Kumar RA, et al: Recurrent 16p11.2 microdeletions in autism. Hum Mol Genet 2008; 17: 628-638.
132. Weiss LA, et al: Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med 2008; 358:667-675.
133. Jacquemont S, et al: Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus. Nature 2011; 478: 97-102.
134. McCarthy SE, et al: Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet 2009; 41: 1223-1227.
135. Horev G, et al: Dosage-dependent phenotypes in models of 16p11.2 lesions found in autism. Proc Natl Acad Sci USA 2011; 108: 17076-17081.
136. Bijlsma EK, et al: Extending the phenotype of recurrent rearrangements of 16p11.2: Deletions in mentally retarded patients without autism and in normal individuals. Eur J Med Genet 2009; 52: 77-87.